Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerBusiness Wire • 16 days ago
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished...
Share to Feed
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of...
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM Research Report) on March 25 and set a price target of $36...
This price move could indicate a change in the trend, and may be a sell signal for investors...
This is a Bullish indicator signaling VSTM's price could rise from here. Traders may explore going long the stock or buying call options...
This price move could indicate a change in the trend, and may be a buy signal for investors...
This price move could indicate a change in the trend, and may be a buy signal for investors...
For the last three days, A.I.dvisor has detected that VSTM's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced new results from the first-ever global LGSOC Patient...